New research highlights strategies to overcome cancer drug resistance: a triple-drug AML combination, a breast cancer resistance target, evolutionary treatment switching, DNA damage mechanisms, and sildenafil's anti-metastatic potential.
Relay Therapeutics reported Q4/FY 2025 results, outlined 2026 milestones for zovegalisib, and held ~$555M in cash. Initial vascular anomaly data and breast cancer triplet data are expected in 2026.
A JAMA Oncology study finds breast cancer patients using complementary and alternative medicine face a higher risk of death. A new molecule SU212 shows promise against triple-negative breast cancer, and global breast cancer cases are projected to rise to 3.5 million by 2050.
The FDA approved six cancer therapies in Q2 2026, including first-line sacituzumab govitecan for triple-negative breast cancer and capivasertib for PTEN-deficient prostate cancer. A separate study shows 69% of accelerated-approval cancer drugs need safety updates within 4 years.
Atezolizumab plus capecitabine showed no significant survival benefit in residual TNBC. Other reports covered HER2-low AR enrichment, first-line ADC choices, and a self-management planner.
FDA's ODAC voted 6-3 against AstraZeneca's camizestrant for HR+/HER2- metastatic breast cancer, citing uncertain clinical benefit from the SERENA-6 trial design. The FDA raised concerns about the early-switch treatment paradigm and long-term outcomes.
ALX Oncology has multiple 2026 catalysts for Evorpacept and ALX2004. Interim ASPEN-09 data are expected in Q3 2026, while an initial safety update from the phase 1 ALX2004 trial is expected in 1H 2026.
The FDA has accepted Roche's new drug application for giredestrant plus everolimus to treat ER-positive, HER2-negative, ESR1-mutated advanced breast cancer following prior endocrine therapy, with a decision expected by December 18, 2026.
New research reveals that over a quarter of healthy years lost to breast cancer are linked to modifiable lifestyle factors, while scientists advance targeted therapies and identify cellular mechanisms behind postpartum breast cancer risk.
Oncolytics Biotech launches Phase 2 trial of pelareorep immunotherapy in metastatic colorectal cancer, following Fast Track Designation and promising earlier results showing 27-month median survival.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07757230 |
A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07726342 |
SMP-656 for HER2-Positive Advanced Breast Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07708194 |
Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure |
RECRUITING | PHASE1/PHASE2 |
| NCT07706179 |
Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07704801 |
CDK4/6 Inhibitors in Metastatic HR-Positive Breast Cancer |
ACTIVE_NOT_RECRUITING | |
| NCT07693985 |
Multimodal Exercise and Education Program in Metastatic Breast CancerMostrar más líneas |
COMPLETED | NA |
| NCT07683754 |
T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd |
NOT_YET_RECRUITING | PHASE3 |
| NCT07676344 |
CRYO-TOUCH: Cryoablation of the Primary Breast Tumor in Metastatic Breast Cancer |
NOT_YET_RECRUITING | NA |
| NCT07648940 |
Bioequivalence Study of Liposomal Doxorubicin 20 mg/10 mL (Doxopeg® vs Caelyx®) in Advanced Cancer Patients |
COMPLETED | PHASE1 |
| NCT07624617 |
Fast-Her: Fasting Effects on Breast Cancer Treatment |
RECRUITING | NA |
